Patents by Inventor Yanping Xiao

Yanping Xiao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • P2X3 andor P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof
    Patent number: 11919918
    Abstract: A P2X3 and/or P2X2/3 receptor antagonist of formula (I), a pharmaceutical composition comprising the same, and a use thereof in preparing a drug for preventing or treating a disease mediated by the P2X3 and/or P2X2/3 receptor antagonist.
    Type: Grant
    Filed: May 27, 2022
    Date of Patent: March 5, 2024
    Assignee: BEIJING TIDE PHARMACEUTICAL CO., LTD.
    Inventors: Yanping Zhao, Hongjun Wang, Gong Li, Xiang Li, Yuanyuan Jiang, Kai Liu, Yeming Wang, Liying Zhou, Yanan Liu, Ning Shao, Fengping Xiao
  • Agents that modulate RGMb-neogenin-BMP signaling and methods of use thereof
    Patent number: 11485787
    Abstract: The present invention relates to compositions and methods for the modulation RGMb-Neogenin-BMP signaling.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: November 1, 2022
    Assignees: Dana-Farber Cancer Institute, Inc., Boston Children's Hospital
    Inventors: Rosemarie Dekruyff, Gordon J. Freeman, Dale Umetsu, Sanhong Yu, Yanping Xiao
  • ANTI-CD137 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220235349
    Abstract: The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: December 30, 2021
    Publication date: July 28, 2022
    Inventors: Yanping Xiao, Nicholas Stuart WILSON, Benjamin Maxime MORIN, Mark Arthur FINDEIS, Cornelia Anne MUNDT, Marc van DIJK, Dhan Sidhartha CHAND, David Adam SAVITSKY, Dennis John UNDERWOOD, Olga IGNATOVICH
  • Agents that modulate immune cell activation and methods of use thereof
    Patent number: 11359020
    Abstract: The present invention relates to compositions and methods for the immunomodulation mediated by the interaction of PD-L2 and RGMb.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: June 14, 2022
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College, Children's Medical Center Corporation
    Inventors: Gordon J. Freeman, Arlene H. Sharpe, Yanping Xiao, Loise Francisco, Rosemarie Dekruyff, Dale Umetsu
  • ANTI-CD137 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220106581
    Abstract: The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: July 19, 2021
    Publication date: April 7, 2022
    Applicants: AGENUS INC., AGENUS INC.
    Inventors: Yanping XIAO, Nicholas Stuart WILSON, Benjamin Maxime MORIN, Mark Arthur FINDEIS, Cornelia Anne MUNDT, Marc van DIJK, Dhan Sidhartha CHAND, David Adam SAVITSKY, Dennis John UNDERWOOD, Olga IGNATOVICH
  • Anti-CD137 antibodies and methods of use thereof
    Patent number: 11242385
    Abstract: The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: February 8, 2022
    Assignee: AGENUS INC.
    Inventors: Yanping Xiao, Nicholas Stuart Wilson, Benjamin Maxime Morin, Mark Arthur Findeis, Cornelia Anne Mundt, Marc van Dijk, Dhan Sidhartha Chand, David Adam Savitsky, Dennis John Underwood, Olga Ignatovich
  • METHODS FOR UPREGULATING IMMUNE RESPONSES USING COMBINATIONS OF ANTI-RGMb AND ANTI-PD-1 AGENTS
    Publication number: 20220033502
    Abstract: The present invention relates to methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents.
    Type: Application
    Filed: August 23, 2021
    Publication date: February 3, 2022
    Inventors: Gordon J. Freeman, Yanping Xiao
  • Methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents
    Patent number: 11220545
    Abstract: The present invention relates to methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: January 11, 2022
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Gordon J. Freeman, Yanping Xiao
  • Anti-CD137 antibodies and methods of use thereof
    Patent number: 11098117
    Abstract: The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: August 24, 2021
    Assignee: Agenus Inc.
    Inventors: Yanping Xiao, Nicholas Stuart Wilson, Benjamin Maxime Morin, Mark Arthur Findeis, Cornelia Anne Mundt, Marc van Dijk, Dhan Sidhartha Chand, David Adam Savitsky, Dennis John Underwood, Olga Ignatovich
  • ANTI-CD137 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20210106693
    Abstract: The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: November 10, 2020
    Publication date: April 15, 2021
    Inventors: Yanping Xiao, Nicholas Stuart Wilson, Benjamin Maxime Morin, Mark Arthur Findeis, Cornelia Anne Mundt, Marc van Dijk, Dhan Sidhartha Chand, David Adam Savitsky, Dennis John Underwood, Olga Ignatovich
  • METHODS FOR TREATING CANCER USING COMBINATIONS OF ANTI-BTNL2 AND IMMUNE CHECKPOINT BLOCKADE AGENTS
    Publication number: 20210032334
    Abstract: The present invention relates, in part, to methods of treating cancers using combinations of anti-BTNL2 and anti-immune checkpoint therapies.
    Type: Application
    Filed: February 27, 2019
    Publication date: February 4, 2021
    Inventors: Gordon J. Freeman, Yanping Xiao
  • AGENTS THAT MODULATE IMMUNE CELL ACTIVATION AND METHODS OF USE THEREOF
    Publication number: 20200095325
    Abstract: The present invention relates to compositions and methods for the immunomodulation mediated by the interaction of PD-L2 and RGMb.
    Type: Application
    Filed: September 16, 2019
    Publication date: March 26, 2020
    Inventors: Gordon J. Freeman, Arlene H. Sharpe, Yanping Xiao, Loise Francisco, Rosemarie Dekruyff, Dale Umetsu
  • Agents that modulate immune cell activation and methods of use thereof
    Patent number: 10457733
    Abstract: The present invention relates to compositions and methods for the immunomodulation mediated by the interaction of PD-L2 and RGMb.
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: October 29, 2019
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Gordon J. Freeman, Arlene H. Sharpe, Yanping Xiao, Loise Francisco, Rosemarie Dekruyff, Dale Umetsu
  • ANTI-CD137 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20180344870
    Abstract: The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: April 12, 2018
    Publication date: December 6, 2018
    Inventors: Yanping Xiao, Nicholas Stuart Wilson, Benjamin Morin, Mark Arthur Findeis, Cornelia Anne Mundt, Marc van Dijk
  • METHODS FOR UPREGULATING IMMUNE RESPONSES USING COMBINATIONS OF ANTI-RGMb AND ANTI-PD-1 AGENTS
    Publication number: 20180002422
    Abstract: The present invention relates to methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents.
    Type: Application
    Filed: December 7, 2015
    Publication date: January 4, 2018
    Inventors: Gordon J. Freeman, Yanping Xiao
  • AGENTS THAT MODULATE RGMb-NEOGENIN-BMP SIGNALING AND METHODS OF USE THEREOF
    Publication number: 20160347844
    Abstract: The present invention relates to compositions and methods for the modulation RGMb-Neogenin-BMP signaling.
    Type: Application
    Filed: February 5, 2015
    Publication date: December 1, 2016
    Inventors: Rosemarie Dekruyff, Gordon J. Freeman, Dale Umetsu, Sanhong Yu, Yanping Xiao
  • Agents That Modulate Immune Cell Activation and Methods of Use Thereof
    Publication number: 20150299322
    Abstract: The present invention relates to compositions and methods for the immunomodulation mediated by the interaction of PD-L2 and RGMb.
    Type: Application
    Filed: August 2, 2013
    Publication date: October 22, 2015
    Applicants: Dana-Farber Cancer Institute, Inc., Boston Children's Hospital, President and Fellows of Harvard College
    Inventors: Gordon J. Freeman, Arlene H. Sharpe, Yanping Xiao, Loise Francisco, Rosemarie Dekruyff, Dale Umetsu
  • Method and apparatus for the production of aluminum
    Patent number: 7867373
    Abstract: Disclosed is a method for the continuous production of aluminum from alumina including a first step of converting alumina (Al2O3) into aluminum sulfide (Al2S3) and a second step of separation of aluminum from aluminum sulfide in a separating reactor. Wherein in the first step in a conversion reactor alumina is dissolved in a molten salt to form a melt and a sulfur containing gas is fed through the melt whereby the sulfur containing gas acts as a reagent to convert at least part of the alumina into aluminum sulfide and at least part of the melt is used in the second step. Further the invention relates to an apparatus for operating the method.
    Type: Grant
    Filed: March 24, 2006
    Date of Patent: January 11, 2011
    Assignee: Aleris Aluminum Koblenz GmbH
    Inventors: Dietrich Willem Van Der Plas, Yanping Xiao
  • Process For the Electrolysis of Aluminiumsulfide
    Publication number: 20080202939
    Abstract: Process for the electrolysis of Al2S3, using a bath of molten salt, preferably a bath of molten chloride salt, in which Al2S3 is dissolved characterized in that measures are taken to improve the electrical conductivity of the bath, so as to enable an increase in the current density in the bath.
    Type: Application
    Filed: March 31, 2004
    Publication date: August 28, 2008
    Applicant: Corus Aluminum Walzprodukte GmbH
    Inventors: Dietrich Willem Van Der Plas, Steven Christian Lans, Markus Andreas Reuter, Mpia Cyril Roger Mambote, Anthonie Van Sandwijk, Yanping Xiao
  • Method and apparatus for the production of aluminium
    Publication number: 20060226026
    Abstract: Disclosed is a method for the continuous production of aluminum from alumina including a first step of converting alumina (Al2O3) into aluminum sulfide (Al2S3) and a second step of separation of aluminum from aluminum sulfide in a separating reactor. Wherein in the first step in a conversion reactor alumina is dissolved in a molten salt to form a melt and a sulfur containing gas is fed through the melt whereby the sulfur containing gas acts as a reagent to convert at least part of the alumina into aluminum sulfide and at least part of the melt is used in the second step. Further the invention relates to an apparatus for operating the method.
    Type: Application
    Filed: March 24, 2006
    Publication date: October 12, 2006
    Applicant: Corus Alumimium Walzprodukte GmbH
    Inventors: Dietrich Van Der Plas, Yanping Xiao